Latest Medical Devices News
Archer Materials Ltd Moves Biochip Into Clinical Device Build Ahead of FDA Meeting
Aroa Biosurgery Ltd Adds Two Senior US Commercial Leaders
Dorsavi Ltd Launches Sensor v6.5 on Body AI Wearable
Imricor Medical Systems Begins U.S. Launch With First Hospital Sale
EBR Systems Launches WiSE Coupler to Bolster U.S. Heart Device Rollout
Cochlear Ltd Retains Duty Free US Access After Section 301 Ruling
Oncosil Medical Ltd Study Supports Higher Concentration Formulations
Polynovo Ltd Posts Record $150m FY26 Revenue as US Sales Hit New High
Medical Devices ETF Chart
Medical Devices Analysis
UBS Backs 3 ASX Healthcare Stocks With Up to 100% Upside
ResMed’s 51% Valuation Discount: Bargain or Fair Re-Rating?
Why ASX Healthcare Fell 16 Points Behind the Market in 5 Years
ResMed Shares Down 19.8%: Valuation Trap or Mispriced Opportunity?
Cochlear at AU$97: Quality Business or Permanent Impairment?
Cochlear Falls 63%: Generational Discount or Falling Knife?
Cochlear Stock: Reading the 70% P/S Compression After the Crash
ResMed Share Price at 52% Discount: Opportunity or Value Trap?
Cochlear at A$95: Bargain or Value Trap for ASX Investors?
Medical Devices Guides & Education
What an 86% Untreated Market Means for ASX Health Stocks
3 ASX Blue Chips Built for Long-Term Compounding
How to Use the Price-to-Sales Ratio Without Getting It Wrong
Discover More in the Medical Technology Hub
Go to Hub
EBR Systems Posts 46 WiSE Implants With US$2.5M to US$2.6M Q2 Revenue Guidance
Archer Materials Ltd Moves Biochip Into Clinical Device Build Ahead of FDA Meeting
Cyclopharm Ltd Technegas Named Preferred in Updated US Lung Imaging Guidelines
Dorsavi Ltd Launches Sensor v6.5 on Body AI Wearable
InteliCare Holdings Ltd Expands Hardi Deal With $371K Nurse Call Rollout
Imricor Medical Systems Begins U.S. Launch With First Hospital Sale
EBR Systems Launches WiSE Coupler to Bolster U.S. Heart Device Rollout
Cochlear Ltd Retains Duty Free US Access After Section 301 Ruling
Polynovo Ltd Posts Record $150m FY26 Revenue as US Sales Hit New High
Featured ASX Medical Devices Announcements
Latest ASX Medical Devices Videos
Medical Equipment Stocks: Industry Trends, Earnings and Investment Analysis
Medical equipment stocks span surgical systems, diagnostic imaging hardware, patient monitoring, and reusable procedural instruments, each with distinct revenue models and competitive barriers. The sector is characterised by long product lifecycles, regulatory moats, and deep hospital relationships that create durable earnings for established players. ASX-listed medical equipment companies have increasingly pursued international expansion to access larger addressable markets. StockWire X tracks earnings results, new product approvals, tender wins, and M&A activity across medical equipment stocks. Capital expenditure cycles in the hospital sector and healthcare funding decisions are key macro drivers our analysis monitors.
Frequently Asked Questions
What are the top 10 medical stocks on the ASX?
The ASX has a comprehensive medical sector spanning pharmaceuticals, medical devices, diagnostics, and health services. Top ASX medical stocks by market cap include globally significant businesses alongside a deep cohort of emerging companies. StockWire X covers ASX medical equipment stocks and the broader healthcare sector with analysis of earnings, clinical milestones, and market developments.
What are small medical device companies worth researching?
Small medical device companies on the ASX and globally offer investors exposure to innovative technology at earlier stages of development, where the return potential is highest. Key assessment criteria include regulatory pathway clarity, addressable market size, manufacturing scalability, and management track record. StockWire X covers small medical device and equipment companies with ongoing news and analysis.
What drives the share price of medical equipment stocks?
Medical equipment stock prices are driven by regulatory approvals and product launches, earnings results relative to guidance, contract and tender wins, acquisition activity, and the capital expenditure cycle in hospital systems. Companies with high recurring consumable and service revenue show more stable share price behaviour than those dependent on lumpy capital equipment sales.
How do hospital capital expenditure cycles affect medical equipment company revenues?
Medical equipment companies selling high-value capital equipment are significantly affected by hospital capital expenditure cycles. During periods of constrained hospital budgets, capital equipment purchases are often deferred, creating revenue headwinds. When hospital finances improve or government funding initiatives stimulate investment, equipment demand accelerates. Investors track hospital sector financial health and government infrastructure spending programmes to anticipate demand conditions.
What is the installed base business model and why is it valued highly in medical equipment investing?
The installed base model involves selling capital equipment competitively to establish a large customer base, then generating recurring, high-margin revenue from consumables, reagents, service contracts, and software. Companies with large installed bases generate predictable recurring revenues that are less cyclically sensitive than capital equipment sales alone. Investors value recurring revenue streams at higher multiples because they are more predictable and have lower customer acquisition costs.
Amplia Therapeutics Ltd Investor Briefing
30 July, 11:00 AM AEST
ASX: ATX
Targeting Pancreatic Cancer and Beyond: Amplia Therapeutics (ASX:ATX) Pancreatic cancer is one of the hardest cancers to treat, but Amplia Therapeutics (ASX:ATX | OTCQB:INNMF) may have found a way to help. Their drug, narmafotinib, works by breaking down the tough fibrous shield around tumours, letting chemotherapy do its job better. Join this investor webinar to hear how the science is playing out in real trials, what the path to FDA approval looks like, and where the company is headed next, including new work in ovarian cancer and a promising new class of cancer drugs called kRAS inhibitors.
You're registered!
Check your inbox for a confirmation email with the calendar invite.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time